KIR2DL2

KIR2DL2 Overview

English Name	Killer cell immunoglobulin-like receptor 2DL2	Approved Drugs	0
Drugs in Clinical Trials	1	Target Synonym	CD158b1 Antigen，CD158b，P58.2，Receptors， KIR2DL2，CD158k，Cl-43，p58 NK receptor CL-43，CD158B1，Natural killer-associated transcript 6，NKAT6，Killer cell immunoglobulin-like receptor 2DL2，KIR2DL2，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 2，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 2，P58 Natural Killer Cell Receptor Clone CL-43，CD158 Antigen-Like Family Member B1，MHC Class I NK Cell Receptor，NKAT-6
Highest Development Stage	Phase 2 Clinical

English Name	Killer cell immunoglobulin-like receptor 2DL2
Target Synonym	CD158b1 Antigen，CD158b，P58.2，Receptors， KIR2DL2，CD158k，Cl-43，p58 NK receptor CL-43，CD158B1，Natural killer-associated transcript 6，NKAT6，Killer cell immunoglobulin-like receptor 2DL2，KIR2DL2，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 2，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 2，P58 Natural Killer Cell Receptor Clone CL-43，CD158 Antigen-Like Family Member B1，MHC Class I NK Cell Receptor，NKAT-6
Approved Drugs	0
Drugs in Clinical Trials	1
Highest Development Stage	Phase 2 Clinical

KIR2DL2 Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
Fc Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature	Order Now
KI2-H5255	Human	HEK293	Human KIR2DL2 / CD158b1 / NKAT-6 Protein, Fc Tag				Add to Cart

Total: 1

KIR2DL2 Background

Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.

KIR2DL2 Synonyms

CD158b1

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details